Quick Answer
Immunovant, Inc. reported Cash and Equivalents of $713.97 million for fiscal year 2025.
Immunovant, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $713.97M | +12.4% |
| 2024 | $635.37M | +68.7% |
| 2023 | $376.53M | -23.8% |
| 2022 | $493.82M | +23.4% |
| 2021 | $400.15M | +297.9% |
| 2020 | $100.57M | +1339.8% |
| 2019 | $6.99M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $994.52M | +165.4% | +90.6% |
| September 30, 2025 | $521.87M | +10.3% | -12.9% |
| June 30, 2025 | $598.91M | +6.9% | -16.1% |
| March 31, 2025 | $713.97M | +12.4% | +90.6% |
| December 31, 2024 | $374.69M | -45.8% | -20.8% |
| September 30, 2024 | $472.94M | +75.2% | -15.5% |
| June 30, 2024 | $560.00M | +69.7% | -11.9% |
| March 31, 2024 | $635.37M | +68.7% | -8.0% |
- Immunovant, Inc. showed an increase of +12.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Immunovant, Inc.’s cash and equivalents has grown by 10121.5% (from $6.99 million to $713.97 million).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: